Development of recombinant human granulocyte colony-stimulating factor (nartograstim) production process in Escherichia coli compatible with industrial scale and with no antibiotics in the culture medium (2021)
- Authors:
- USP affiliated authors: MAKIYAMA, EDSON NAOTO - FCF ; GARCIA, PRIMAVERA BORELLI - FCF ; BARAZZONE, GIOVANA CAPPIO - Interunidades em Biotecnologia ; HO, PAULO LEE - IQ ; GONÇALVES, VIVIANE MAIMONI - Interunidades em Biotecnologia
- Unidades: FCF; Interunidades em Biotecnologia; IQ
- DOI: 10.1007/s00253-020-11014-y
- Subjects: GRANULÓCITOS; ESCHERICHIA COLI
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Applied Microbiology and Biotechnology
- ISSN: The granulocyte colony-stimulating factor (G-CSF) is a hematopoietic cytokine that has important clinical applications for treating neutropenia. Nartograstim is a recombinant variant of human G-CSF. Nartograstim has been produced in Escherichia coli as inclusion bodies (IB) and presents higher stability and biological activity than the wild type of human G-CSF because of its mutations. We developed a production process of nartograstim in a 10-L bioreactor using auto-induction or chemically defined medium. After cell lysis, centrifugation, IB washing, and IB solubilization, the following three refolding methods were evaluated: diafiltration, dialysis, and direct dilution in two refolding buffers.Western blot and SDS-PAGE confirmed the identity of 18.8-kDa bands as nartograstim in both cultures. The auto-induction medium produced 1.17 g/L and chemically defined medium produced 0.95 g/L. The dilution method yielded the highest percentage of refolding (99%). After refolding, many contaminant proteins precipitated during pH adjustment to 5.2, increasing purity from 50 to 78%. After applying the supernatant to cation exchange chromatography (CEC), nartograstim recovery was low and the purity was 87%. However, when the refolding solution was applied to anion exchange chromatography followed by CEC, 91%–98%purity and 2.2%recovery were obtained. The purification process described in this work can be used to obtain nartograstim with high purity, structural integrity, and the expected biological activity
- Volume/Número/Paginação/Ano: v. 105, p. 169–183, 2021
- Status:
- Artigo possui versão em acesso aberto em repositório (Green Open Access)
- Versão do Documento:
- Versão submetida (Pré-print)
- Acessar versão aberta:
-
ABNT
EGUIA, Fara A. P et al. Development of recombinant human granulocyte colony-stimulating factor (nartograstim) production process in Escherichia coli compatible with industrial scale and with no antibiotics in the culture medium. Applied Microbiology and Biotechnology, v. 105, p. 169–183, 2021Tradução . . Disponível em: https://doi.org/10.1007/s00253-020-11014-y. Acesso em: 08 abr. 2026. -
APA
Eguia, F. A. P., Mascarelli, D. E., Carvalho, E. de, Rodríguez, G. R., Makiyama, E. N., Borelli, P., et al. (2021). Development of recombinant human granulocyte colony-stimulating factor (nartograstim) production process in Escherichia coli compatible with industrial scale and with no antibiotics in the culture medium. Applied Microbiology and Biotechnology, 105, 169–183. doi:10.1007/s00253-020-11014-y -
NLM
Eguia FAP, Mascarelli DE, Carvalho E de, Rodríguez GR, Makiyama EN, Borelli P, Lieberman C, Ho PL, Barazzone GC, Gonçalves VM. Development of recombinant human granulocyte colony-stimulating factor (nartograstim) production process in Escherichia coli compatible with industrial scale and with no antibiotics in the culture medium [Internet]. Applied Microbiology and Biotechnology. 2021 ; 105 169–183.[citado 2026 abr. 08 ] Available from: https://doi.org/10.1007/s00253-020-11014-y -
Vancouver
Eguia FAP, Mascarelli DE, Carvalho E de, Rodríguez GR, Makiyama EN, Borelli P, Lieberman C, Ho PL, Barazzone GC, Gonçalves VM. Development of recombinant human granulocyte colony-stimulating factor (nartograstim) production process in Escherichia coli compatible with industrial scale and with no antibiotics in the culture medium [Internet]. Applied Microbiology and Biotechnology. 2021 ; 105 169–183.[citado 2026 abr. 08 ] Available from: https://doi.org/10.1007/s00253-020-11014-y - Autophagy is required for hemopoietic stem cell survival in protein malnutrition
- Estudo de uma nova rota sintética para o fármaco (R)-Baclofen 'Marca registrada'
- Purificação de catalase a partir de placentas humanas
- Cultivo de Streptococcus pneumoniae sorotipo 23F: produção e purificação de seu polissacarídeo capsular para formulação de vacinas
- Purificacao e caracterizacao de fibroblast growth factors (fg fs) a partir de hipofises bovinas
- A desnutrição proteica altera o perfil de diferenciação mieloide da célula tronco hematopoética: participação das células endoteliais medulares
- Direct ionizing radiation and bystander effect in mouse mesenchymal stem cells
- Endothelial like cells derived from bone marrow nes+ mesenchymal stem cells have a sinusoidal perivascular phenotype
- Impairment of G-CSF receptor on granulocytic progenitor cells causes neutropenia in protein malnutrition
- CXCL12 production by bone marrow 'NES POT. +' MSCS is downregulated in malnourished mice
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
